# A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients

> **NCT06513546** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **PLL TX AUSTRALIA PTY LTD** · enrollment: 153 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- ALS

## Interventions

- **DRUG:** PLL001 or placebo daily subcutaneous injections

## Key facts

- **NCT ID:** NCT06513546
- **Lead sponsor:** PLL TX AUSTRALIA PTY LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-08
- **Primary completion:** 2026-12-15
- **Final completion:** 2027-06-15
- **Target enrollment:** 153 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06513546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06513546, "A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06513546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*